Back to News
Oct 28, 2025 4:00 PM

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

DXCM is lagging behind market performance. Get the complete picture here.

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device.

Some patients reportedly experienced severe complications, including hospitalizations and fatalities.

Also Read: Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

After the report surfaced in September, two law firms launched class action lawsuits ...